ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
45K |
5 |
15/05/23 |
15/05/23 |
ASX - By Stock
|
219
|
45K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
45K |
1 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
219
|
45K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
45K |
0 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
219
|
45K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
45K |
1 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
219
|
45K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Twiggy's Invex Therapeutics | The Imminent Coin Flip
|
|
SSilverstein
|
219 |
45K |
6 |
03/05/23 |
03/05/23 |
ASX - By Stock
|
219
|
45K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Top 20 Holders
|
|
SSilverstein
|
89 |
24K |
2 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
89
|
24K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Invex Receives Regulatory Approval for IIH EVOLVE in France
|
|
SSilverstein
|
11 |
3.4K |
1 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
11
|
3.4K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
3 |
21/04/23 |
21/04/23 |
ASX - By Stock
|
241
|
48K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
7 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
241
|
48K
|
7
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
SSilverstein
|
9 |
2.0K |
4 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
9
|
2.0K
|
4
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Israel Ministry of Health Approval for IIH EVOLVE
|
|
SSilverstein
|
4 |
1.2K |
3 |
20/04/23 |
20/04/23 |
ASX - By Stock
|
4
|
1.2K
|
3
|
|
ASX - By Stock
|
AAC |
Re:
Ann: FY23 Half Year Financial Report
|
|
SSilverstein
|
8 |
4.4K |
1 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
8
|
4.4K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: First Patient Randomised in IIH EVOLVE Phase III Trial
|
|
SSilverstein
|
55 |
10K |
2 |
18/04/23 |
18/04/23 |
ASX - By Stock
|
55
|
10K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notification of cessation of securities - IXC
|
|
SSilverstein
|
16 |
2.1K |
1 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
16
|
2.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notification of cessation of securities - IXC
|
|
SSilverstein
|
16 |
2.1K |
0 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
16
|
2.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Notification of cessation of securities - IXC
|
|
SSilverstein
|
16 |
2.1K |
1 |
14/04/23 |
14/04/23 |
ASX - By Stock
|
16
|
2.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
1 |
06/04/23 |
06/04/23 |
ASX - By Stock
|
241
|
48K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
02/04/23 |
02/04/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
IXC Trial Patient "Begged" Professor to Let Her Stay On the Drug After P2 Trial Ended
|
|
SSilverstein
|
10 |
2.0K |
1 |
31/03/23 |
31/03/23 |
ASX - By Stock
|
10
|
2.0K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
0 |
30/03/23 |
30/03/23 |
ASX - By Stock
|
241
|
48K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
6 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
241
|
48K
|
6
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
2 |
28/03/23 |
28/03/23 |
ASX - By Stock
|
241
|
48K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial
|
|
SSilverstein
|
22 |
5.9K |
2 |
25/03/23 |
25/03/23 |
ASX - By Stock
|
22
|
5.9K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial
|
|
SSilverstein
|
22 |
5.9K |
3 |
25/03/23 |
25/03/23 |
ASX - By Stock
|
22
|
5.9K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Fundamental Analysis Discussion Only (IXC Thread)
|
|
SSilverstein
|
40 |
9.4K |
3 |
19/03/23 |
19/03/23 |
ASX - By Stock
|
40
|
9.4K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Fundamental Analysis Discussion Only (IXC Thread)
|
|
SSilverstein
|
40 |
9.4K |
0 |
19/03/23 |
19/03/23 |
ASX - By Stock
|
40
|
9.4K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Publication of Invex IIH Phase II Pressure Trial Results
|
|
SSilverstein
|
20 |
4.0K |
1 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
20
|
4.0K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Publication of Invex IIH Phase II Pressure Trial Results
|
|
SSilverstein
|
20 |
4.0K |
0 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
20
|
4.0K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
5 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
26
|
6.1K
|
5
|
|
ASX - By Stock
|
IXC |
Re:
Ann: Publication of Invex IIH Phase II Pressure Trial Results
|
|
SSilverstein
|
20 |
4.0K |
2 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
20
|
4.0K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
1 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
241
|
48K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
1 |
09/03/23 |
09/03/23 |
ASX - By Stock
|
241
|
48K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
1 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
241
|
48K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
2 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
26
|
6.1K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
0 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
26
|
6.1K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
1 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
26
|
6.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
1 |
07/03/23 |
07/03/23 |
ASX - By Stock
|
26
|
6.1K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
2 |
03/03/23 |
03/03/23 |
ASX - By Stock
|
241
|
48K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
1 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
241
|
48K
|
1
|
|
ASX - By Stock
|
IXC |
Re:
DCF Valuation Model for Invex Therapeutics
|
|
SSilverstein
|
241 |
48K |
2 |
01/03/23 |
01/03/23 |
ASX - By Stock
|
241
|
48K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Invex Tx is hiring a CMO
|
|
SSilverstein
|
10 |
2.2K |
0 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
10
|
2.2K
|
0
|
|
ASX - By Stock
|
IXC |
Re:
What is IXC Management doing well ?
|
|
SSilverstein
|
26 |
6.1K |
3 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
26
|
6.1K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Moderated
|
|
SSilverstein
|
88 |
12K |
3 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
88
|
12K
|
3
|
|
ASX - By Stock
|
IXC |
Re:
Moderated
|
|
SSilverstein
|
88 |
12K |
2 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
88
|
12K
|
2
|
|
ASX - By Stock
|
IXC |
Re:
Moderated
|
|
SSilverstein
|
88 |
12K |
1 |
27/02/23 |
27/02/23 |
ASX - By Stock
|
88
|
12K
|
1
|
|